People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.
of those surveyed in health monitor 2019 rated the quality of healthcare in Switzerland as good.
Quality before costs, less willingness to do without
are numerous diseases that often used to prove serious or fatal for patients, for example hepatitis C, thanks to innovative medicines.
show more articles
The chances of a cure for cancer in children have risen from 40% to 80% between 1973 and 2012.
francs is the total of direct and indirect value added contributed by the pharmaceutical production and research activities. This corresponds to 9.3% of Switzerland's total economic output.
Our mission is to ensure that patients in Switzerland receive access to innovative medicines and therapies as quickly as possible.
The pharmaceutical industry in Switzerland will also need attractive framework conditions in future, including legal certainty, open export markets and the availability of labour.
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2020
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives